HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo

Cancer Cell

Volumn 12, Issue 3, 2007, Pages 230-238

  Gao, Ping ^a   Zhang, Huafeng ^a   Dinavahi, Ramani ^a   Li, Feng ^a   Xiang, Yan ^a   Raman, Venu ^a   Bhujwalla, Zaver M ^a   Felsher, Dean W ^b   Cheng, Linzhao ^a   Pevsner, Jonathan ^a   Lee, Linda A ^a   Semenza, Gregg L ^a   Dang, Chi V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; DOXYCYCLINE; HYPOXIA INDUCIBLE FACTOR 1; MUTANT PROTEIN; MYC PROTEIN; OXYGEN; PROTEIN PROLYL HYDROXYLASE 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 34548257176     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.08.004     Document Type: Article

References (40)

1. Aitio M.L. N-acetylcysteine-passe-partout or much ado about nothing?. Br. J. Clin. Pharmacol. 61 (2006) 5-15
2. Beer S., Zetterberg A., Ihrie R.A., McTaggart R.A., Yang Q., Bradon N., Arvanitis C., Attardi L.D., Feng S., Ruebner B., et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2 (2004) e332 10.1371/journal.pbio.0020332 Published online September 28, 2004
3. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22 (2003) 4082-4090
4. Brahimi-Horn M.C., Chiche J., and Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19 (2007) 223-229
5. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., Scarpulla R.C., and Chandel N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1 (2005) 409-414
6. Cameron E., Pauling L., and Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res. 39 (1979) 663-681
7. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., and Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443 (2006) 214-217
8. Covello K.L., and Simon M.C. HIFs, hypoxia, and vascular development. Curr. Top. Dev. Biol. 62 (2004) 37-54
9. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2 (2003) 803-811
10. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., and Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11 (2007) 335-347
11. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., Simon M.C., Hammerling U., and Schumacker P.T. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1 (2005) 401-408
12. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23 (2003) 9361-9374
13. Hummel M., Bentink S., Berger H., Klapper W., Wessendorf S., Barth T.F., Bernd H.W., Cogliatti S.B., Dierlamm J., Feller A.C., et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354 (2006) 2419-2430
14. Kaelin W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74 (2005) 115-128
15. Kaelin Jr. W.G. ROS: really involved in oxygen sensing. Cell Metab. 1 (2005) 357-358
16. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., and Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101 (2003) 2797-2803
17. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., Rowan A., Yan Z., Campochiaro P.A., and Semenza G.L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93 (2003) 1074-1081
18. Knowles H.J., Raval R.R., Harris A.L., and Ratcliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63 (2003) 1764-1768
19. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., and Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23 (2004) 1949-1956
20. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., and Huang L.E. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 17 (2005) 793-803
21. Krishnamachary B., Zagzag D., Nagasawa H., Rainey K., Okuyama H., Baek J.H., and Semenza G.L. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66 (2006) 2725-2731
22. Limoli C.L., Giedzinski E., Morgan W.F., Swarts S.G., Jones G.D., and Hyun W. Persistent oxidative stress in chromosomally unstable cells. Cancer Res. 63 (2003) 3107-3111
23. Liu Y.V., Baek J.H., Zhang H., Diez R., Cole R.N., and Semenza G.L. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol. Cell 25 (2007) 207-217
24. Louis S.F., Vermolen B.J., Garini Y., Young I.T., Guffei A., Lichtensztejn Z., Kuttler F., Chuang T.C., Moshir S., Mougey V., et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc. Natl. Acad. Sci. USA 102 (2005) 9613-9618
25. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., and Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 280 (2005) 41928-41939
26. Mantovani G., Maccio A., Madeddu C., Mura L., Gramignano G., Lusso M.R., Massa E., Mocci M., and Serpe R. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J. Mol. Med. 81 (2003) 664-673
27. Narayanan B.A. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr. Cancer Drug Targets 6 (2006) 711-727
28. Pauling L., Nixon J.C., Stitt F., Marcuson R., Dunham W.B., Barth R., Bensch K., Herman Z.S., Blaisdell B.E., Tsao C., et al. Effect of dietary ascorbic acid on the incidence of spontaneous mammary tumors in RIII mice. Proc. Natl. Acad. Sci. USA 82 (1985) 5185-5189
29. Poirier M.C. Chemical-induced DNA damage and human cancer risk. Nat. Rev. Cancer 4 (2004) 630-637
30. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
31. Raman V., Artemov D., Pathak A.P., Winnard Jr. P.T., McNutt S., Yudina A., Bogdanov Jr. A., and Bhujwalla Z.M. Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res. 66 (2006) 9929-9936
32. Reliene R., and Schiestl R.H. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst.) 5 (2006) 852-859
33. Reliene R., Fischer E., and Schiestl R.H. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 64 (2004) 5148-5153
34. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005) 1306-1313
35. Sander S., Bullinger L., Karlsson A., Giuriato S., Hernandez-Boussard T., Felsher D.W., and Pollack J.R. Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Oncogene 24 (2005) 6101-6107
36. Schuhmacher M., Staege M.S., Pajic A., Polack A., Weidle U.H., Bornkamm G.W., Eick D., and Kohlhuber F. Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9 (1999) 1255-1258
37. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
38. Sharma R.A., and Farmer P.B. Biological relevance of adduct detection to the chemoprevention of cancer. Clin. Cancer Res. 10 (2004) 4901-4912
39. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., and Wahl G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9 (2002) 1031-1044
40. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., and Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11 (2007) 407-420